Ingenium Therapeutics, a leading innovator in next-generation NK cell therapies, announced today that its investigational therapy IGNK001 (Gengluecel) has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML).
Ingenium’s proprietary technology enables the company to differentiate and proliferate natural killer (NK) cells with superior anti-cancer efficacy. By targeting CD3-negative immune cells, the company can acquire a large number of highly pure NK cells in a relatively short timeframe.
This mass-produced, allogeneic NK cell therapy derived from healthy donors demonstrates potent anti-cancer effects with high purity and activity.
